Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)

Masatoshi Kudo, Masafumi Ikeda, Kazuomi Ueshima, Michiie Sakamoto, Shuichiro Shiina, Ryosuke Tateishi, Kiyoshi Hasegawa, Junji Furuse, Shiro Miyayama, Takamichi Murakami, Tatsuya Yamashita, Norihiro Kokudo

Research output: Contribution to journalArticle

Abstract

Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation and transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2019 by the Liver Cancer Study Group of Japan based on the 2015 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2019 are as follows: (i) CEA and CA19-9 have been newly added as tumor markers that should be recorded for use as criteria in the response evaluation for intrahepatic cholangiocarcinoma; (ii) the criteria now state that the details of molecular targeted therapy should be specified; and (iii) specific methods for overall evaluation are now described. Also, as an assessment of overall TE4 requires that TE4 is achieved in all nodules (even non-target lesions), the same calculation methods described above are used. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally.

Original languageEnglish
JournalHepatology Research
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Japan
Therapeutics
Clinical Trials
Molecular Targeted Therapy
Cholangiocarcinoma
Tumor Biomarkers
Necrosis
Neoplasms

Keywords

  • Liver Cancer Study Group of Japan
  • modified Response Evaluation Criteria in Solid Tumors
  • Response Evaluation Criteria in Cancer of the Liver
  • Response Evaluation Criteria in Solid Tumors

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). / Kudo, Masatoshi; Ikeda, Masafumi; Ueshima, Kazuomi; Sakamoto, Michiie; Shiina, Shuichiro; Tateishi, Ryosuke; Hasegawa, Kiyoshi; Furuse, Junji; Miyayama, Shiro; Murakami, Takamichi; Yamashita, Tatsuya; Kokudo, Norihiro.

In: Hepatology Research, 01.01.2019.

Research output: Contribution to journalArticle

Kudo, M, Ikeda, M, Ueshima, K, Sakamoto, M, Shiina, S, Tateishi, R, Hasegawa, K, Furuse, J, Miyayama, S, Murakami, T, Yamashita, T & Kokudo, N 2019, 'Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)', Hepatology Research. https://doi.org/10.1111/hepr.13394
Kudo, Masatoshi ; Ikeda, Masafumi ; Ueshima, Kazuomi ; Sakamoto, Michiie ; Shiina, Shuichiro ; Tateishi, Ryosuke ; Hasegawa, Kiyoshi ; Furuse, Junji ; Miyayama, Shiro ; Murakami, Takamichi ; Yamashita, Tatsuya ; Kokudo, Norihiro. / Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). In: Hepatology Research. 2019.
@article{e77598b551e148f6a9caa254068ab7d3,
title = "Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)",
abstract = "Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation and transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2019 by the Liver Cancer Study Group of Japan based on the 2015 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2019 are as follows: (i) CEA and CA19-9 have been newly added as tumor markers that should be recorded for use as criteria in the response evaluation for intrahepatic cholangiocarcinoma; (ii) the criteria now state that the details of molecular targeted therapy should be specified; and (iii) specific methods for overall evaluation are now described. Also, as an assessment of overall TE4 requires that TE4 is achieved in all nodules (even non-target lesions), the same calculation methods described above are used. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally.",
keywords = "Liver Cancer Study Group of Japan, modified Response Evaluation Criteria in Solid Tumors, Response Evaluation Criteria in Cancer of the Liver, Response Evaluation Criteria in Solid Tumors",
author = "Masatoshi Kudo and Masafumi Ikeda and Kazuomi Ueshima and Michiie Sakamoto and Shuichiro Shiina and Ryosuke Tateishi and Kiyoshi Hasegawa and Junji Furuse and Shiro Miyayama and Takamichi Murakami and Tatsuya Yamashita and Norihiro Kokudo",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/hepr.13394",
language = "English",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)

AU - Kudo, Masatoshi

AU - Ikeda, Masafumi

AU - Ueshima, Kazuomi

AU - Sakamoto, Michiie

AU - Shiina, Shuichiro

AU - Tateishi, Ryosuke

AU - Hasegawa, Kiyoshi

AU - Furuse, Junji

AU - Miyayama, Shiro

AU - Murakami, Takamichi

AU - Yamashita, Tatsuya

AU - Kokudo, Norihiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation and transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2019 by the Liver Cancer Study Group of Japan based on the 2015 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2019 are as follows: (i) CEA and CA19-9 have been newly added as tumor markers that should be recorded for use as criteria in the response evaluation for intrahepatic cholangiocarcinoma; (ii) the criteria now state that the details of molecular targeted therapy should be specified; and (iii) specific methods for overall evaluation are now described. Also, as an assessment of overall TE4 requires that TE4 is achieved in all nodules (even non-target lesions), the same calculation methods described above are used. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally.

AB - Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation and transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2019 by the Liver Cancer Study Group of Japan based on the 2015 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2019 are as follows: (i) CEA and CA19-9 have been newly added as tumor markers that should be recorded for use as criteria in the response evaluation for intrahepatic cholangiocarcinoma; (ii) the criteria now state that the details of molecular targeted therapy should be specified; and (iii) specific methods for overall evaluation are now described. Also, as an assessment of overall TE4 requires that TE4 is achieved in all nodules (even non-target lesions), the same calculation methods described above are used. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally.

KW - Liver Cancer Study Group of Japan

KW - modified Response Evaluation Criteria in Solid Tumors

KW - Response Evaluation Criteria in Cancer of the Liver

KW - Response Evaluation Criteria in Solid Tumors

UR - http://www.scopus.com/inward/record.url?scp=85070194270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070194270&partnerID=8YFLogxK

U2 - 10.1111/hepr.13394

DO - 10.1111/hepr.13394

M3 - Article

AN - SCOPUS:85070194270

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

ER -